JP5139306B2 - 電位依存性ナトリウムチャネルの調節因子としての第四級α−アミノカルボキサミド誘導体 - Google Patents
電位依存性ナトリウムチャネルの調節因子としての第四級α−アミノカルボキサミド誘導体 Download PDFInfo
- Publication number
- JP5139306B2 JP5139306B2 JP2008534911A JP2008534911A JP5139306B2 JP 5139306 B2 JP5139306 B2 JP 5139306B2 JP 2008534911 A JP2008534911 A JP 2008534911A JP 2008534911 A JP2008534911 A JP 2008534911A JP 5139306 B2 JP5139306 B2 JP 5139306B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- phenyl
- oxy
- fluorophenyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(CC(*)C(*)*1)(CC1C(C*C1)NC1(*)C(N(*)*)=O)*1CCCCCCC1 Chemical compound CC(CC(*)C(*)*1)(CC1C(C*C1)NC1(*)C(N(*)*)=O)*1CCCCCCC1 0.000 description 7
- CSTNOBRIUPZWHV-UHFFFAOYSA-N CC(C)(C)CS(C)OCC(CCC1c(cc2)ccc2OCc(cccc2)c2F)(C(OC)=O)N1C(OCc1ccccc1)=O Chemical compound CC(C)(C)CS(C)OCC(CCC1c(cc2)ccc2OCc(cccc2)c2F)(C(OC)=O)N1C(OCc1ccccc1)=O CSTNOBRIUPZWHV-UHFFFAOYSA-N 0.000 description 1
- KJTONOYUAYFBJL-JIPXPUAJSA-N CC(C)(C)OC(N([C@H](CC1)c(cc2)cc(OC)c2OCc(cccc2)c2F)[C@]1(COC)C(OC)=O)=O Chemical compound CC(C)(C)OC(N([C@H](CC1)c(cc2)cc(OC)c2OCc(cccc2)c2F)[C@]1(COC)C(OC)=O)=O KJTONOYUAYFBJL-JIPXPUAJSA-N 0.000 description 1
- IDVUUWPEDQFZBT-DYVFJYSZSA-N CC(C)(C)OC(N([C@H](CC1)c(cc2)ccc2O)[C@]1(C)C(N)=O)=O Chemical compound CC(C)(C)OC(N([C@H](CC1)c(cc2)ccc2O)[C@]1(C)C(N)=O)=O IDVUUWPEDQFZBT-DYVFJYSZSA-N 0.000 description 1
- VOLSDCYJMKBKPB-KCWPFWIISA-N CC(C)(C)OC(N([C@H](CC1)c(cc2)ccc2OCc(cccc2)c2F)[C@]1(CC=C)C(OC)=O)=O Chemical compound CC(C)(C)OC(N([C@H](CC1)c(cc2)ccc2OCc(cccc2)c2F)[C@]1(CC=C)C(OC)=O)=O VOLSDCYJMKBKPB-KCWPFWIISA-N 0.000 description 1
- UADFZULVNDQFIG-ATIYNZHBSA-N CC(C)(C)OC(N([C@H](CC1)c(cc2)ccc2OCc(cccc2)c2F)[C@]1(CC=O)C(OC)=O)=O Chemical compound CC(C)(C)OC(N([C@H](CC1)c(cc2)ccc2OCc(cccc2)c2F)[C@]1(CC=O)C(OC)=O)=O UADFZULVNDQFIG-ATIYNZHBSA-N 0.000 description 1
- WTZWOCFLZOQHCE-FQEVSTJZSA-N CC(C)(C)OC(N[C@@H](CCC(c(cc1)ccc1OCc(cccc1)c1F)=O)C(OC)=O)=O Chemical compound CC(C)(C)OC(N[C@@H](CCC(c(cc1)ccc1OCc(cccc1)c1F)=O)C(OC)=O)=O WTZWOCFLZOQHCE-FQEVSTJZSA-N 0.000 description 1
- RHZIGQBDFIOPAH-RBUKOAKNSA-N CCOC([C@@H](CC1)N[C@@H]1c(cc1)ccc1OCc1ccccc1)=O Chemical compound CCOC([C@@H](CC1)N[C@@H]1c(cc1)ccc1OCc1ccccc1)=O RHZIGQBDFIOPAH-RBUKOAKNSA-N 0.000 description 1
- WIJXKEOLJPTMOS-KRWDZBQOSA-N COC([C@H](CC1)N=C1c(cc1OC)ccc1OCc1ccccc1F)=O Chemical compound COC([C@H](CC1)N=C1c(cc1OC)ccc1OCc1ccccc1F)=O WIJXKEOLJPTMOS-KRWDZBQOSA-N 0.000 description 1
- ZFIWHRVUNDUPLE-UHFFFAOYSA-N COC(c1cccc(-c(cc2)ccc2OCc(cccc2)c2F)n1)=O Chemical compound COC(c1cccc(-c(cc2)ccc2OCc(cccc2)c2F)n1)=O ZFIWHRVUNDUPLE-UHFFFAOYSA-N 0.000 description 1
- XXRRODGDWJXPRI-UHFFFAOYSA-N Fc1ccccc1COc(cc1)ccc1Br Chemical compound Fc1ccccc1COc(cc1)ccc1Br XXRRODGDWJXPRI-UHFFFAOYSA-N 0.000 description 1
- SMPXCHFZGCEVTB-UHFFFAOYSA-N O=C1NCCC1(CCC1)NC1c(cc1)ccc1OCc(cccc1)c1F Chemical compound O=C1NCCC1(CCC1)NC1c(cc1)ccc1OCc(cccc1)c1F SMPXCHFZGCEVTB-UHFFFAOYSA-N 0.000 description 1
- SMPXCHFZGCEVTB-FPOVZHCZSA-N O=C1NCC[C@]1(CCC1)N[C@@H]1c(cc1)ccc1OCc(cccc1)c1F Chemical compound O=C1NCC[C@]1(CCC1)N[C@@H]1c(cc1)ccc1OCc(cccc1)c1F SMPXCHFZGCEVTB-FPOVZHCZSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0520578A GB0520578D0 (en) | 2005-10-10 | 2005-10-10 | Novel compounds |
| GB0520578.6 | 2005-10-10 | ||
| GB0523030.5 | 2005-11-11 | ||
| GB0523030A GB0523030D0 (en) | 2005-11-11 | 2005-11-11 | Novel compounds |
| GB0603897.0 | 2006-02-27 | ||
| GB0603897A GB0603897D0 (en) | 2006-02-27 | 2006-02-27 | Novel compounds |
| GB0609159.9 | 2006-05-09 | ||
| GB0609159A GB0609159D0 (en) | 2006-05-09 | 2006-05-09 | Novel Compounds |
| GB0618511A GB0618511D0 (en) | 2006-09-20 | 2006-09-20 | Novel compounds |
| GB0618511.0 | 2006-09-20 | ||
| PCT/EP2006/009732 WO2007042240A1 (en) | 2005-10-10 | 2006-10-06 | Quaternary alpha-aminocarboxamide derivatives as modulators of voltage-gated sodium channels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009514801A JP2009514801A (ja) | 2009-04-09 |
| JP2009514801A5 JP2009514801A5 (cg-RX-API-DMAC7.html) | 2009-11-26 |
| JP5139306B2 true JP5139306B2 (ja) | 2013-02-06 |
Family
ID=37762326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008534911A Expired - Fee Related JP5139306B2 (ja) | 2005-10-10 | 2006-10-06 | 電位依存性ナトリウムチャネルの調節因子としての第四級α−アミノカルボキサミド誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7803833B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1934176B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5139306B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080059297A (cg-RX-API-DMAC7.html) |
| AR (1) | AR057869A1 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE543797T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006301471A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0617189A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2625763A1 (cg-RX-API-DMAC7.html) |
| CR (1) | CR9926A (cg-RX-API-DMAC7.html) |
| EA (1) | EA200801068A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2381686T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL190544A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20082122L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ567030A (cg-RX-API-DMAC7.html) |
| PE (1) | PE20070495A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW200728258A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007042240A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200730494A (en) * | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| WO2007042250A1 (en) * | 2005-10-10 | 2007-04-19 | Glaxo Group Limited | Prolinamide derivatives as sodium channel modulators |
| GB0701365D0 (en) * | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0701366D0 (en) * | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) * | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
| ES2536694T3 (es) | 2009-09-14 | 2015-05-27 | Convergence Pharmaceuticals Limited | Procedimiento para preparar derivados de alfa-carboxamida |
| JP2011232320A (ja) * | 2009-10-01 | 2011-11-17 | Sony Corp | 生体内物質検出用プローブ、および該生体内物質検出用プローブを用いた生体内物質検出装置 |
| ES2786298T3 (es) | 2011-03-03 | 2020-10-09 | Zalicus Pharmaceuticals Ltd | Inhibidores de benzimidazol del canal de sodio |
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) * | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| GB201209670D0 (en) * | 2012-05-31 | 2012-07-18 | Convergence Pharmaceuticals | Novel compounds |
| US10421716B2 (en) | 2014-12-23 | 2019-09-24 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide pyrrolidine derivatives |
| WO2016160574A2 (en) * | 2015-03-27 | 2016-10-06 | Scifluor Life Sciences, Inc. | Aryl- and heteroaryl-pyrrolidine-2-carboxamide compounds |
| MX2020003811A (es) | 2017-10-05 | 2021-01-15 | Biogen Inc | Proceso para preparar derivados de alfa-carboxamida pirrolidina. |
| WO2019075073A2 (en) | 2017-10-10 | 2019-04-18 | Biogen Inc. | PROCESS FOR THE PREPARATION OF SPIRO DERIVATIVES |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL94466A (en) | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| US6201016B1 (en) | 1994-06-27 | 2001-03-13 | Cytomed Incorporated | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders |
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| YU68701A (sh) | 1999-03-26 | 2004-09-03 | Euro-Celtique S.A. | Aril supstituisani pirazoli, imidazoli, oksazoli, tiazoli i piroli i njihova upotreba |
| AR037233A1 (es) * | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
| TW200404796A (en) * | 2002-08-19 | 2004-04-01 | Ono Pharmaceutical Co | Nitrogen-containing compound |
| PA8583001A1 (es) * | 2002-09-20 | 2004-04-23 | Hoffmann La Roche | Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b |
| MY142651A (en) | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| US7589116B2 (en) | 2003-04-03 | 2009-09-15 | Merck & Co. Inc. | Biaryl substituted pyrazoles as sodium channel blockers |
| AU2004232936B2 (en) | 2003-04-18 | 2008-10-30 | Merck & Co., Inc. | Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| US20060217365A1 (en) * | 2003-07-02 | 2006-09-28 | Astrazeneca Ab | Method of treating mood disorders |
| EP1524265A1 (en) * | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors |
| EP1877381A1 (en) | 2005-05-04 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Pyridines useful as modulators of ion channels |
| WO2006119451A1 (en) | 2005-05-04 | 2006-11-09 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyrazines useful as modulators of ion channels |
| JP2008540665A (ja) | 2005-05-19 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとして有用なビアリール |
| GB0701365D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| CA2676357A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
| GB0706630D0 (en) | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
-
2006
- 2006-10-05 TW TW095136996A patent/TW200728258A/zh unknown
- 2006-10-06 EA EA200801068A patent/EA200801068A1/ru unknown
- 2006-10-06 US US11/570,564 patent/US7803833B2/en active Active
- 2006-10-06 AU AU2006301471A patent/AU2006301471A1/en not_active Abandoned
- 2006-10-06 PE PE2006001224A patent/PE20070495A1/es not_active Application Discontinuation
- 2006-10-06 BR BRPI0617189-3A patent/BRPI0617189A2/pt not_active IP Right Cessation
- 2006-10-06 JP JP2008534911A patent/JP5139306B2/ja not_active Expired - Fee Related
- 2006-10-06 NZ NZ567030A patent/NZ567030A/en unknown
- 2006-10-06 WO PCT/EP2006/009732 patent/WO2007042240A1/en not_active Ceased
- 2006-10-06 ES ES06806111T patent/ES2381686T3/es active Active
- 2006-10-06 EP EP06806111A patent/EP1934176B1/en active Active
- 2006-10-06 KR KR1020087011273A patent/KR20080059297A/ko not_active Withdrawn
- 2006-10-06 AT AT06806111T patent/ATE543797T1/de active
- 2006-10-06 CA CA002625763A patent/CA2625763A1/en not_active Abandoned
- 2006-10-09 AR ARP060104440A patent/AR057869A1/es active IP Right Grant
-
2008
- 2008-03-31 IL IL190544A patent/IL190544A/en active IP Right Grant
- 2008-04-25 CR CR9926A patent/CR9926A/es not_active Application Discontinuation
- 2008-05-06 NO NO20082122A patent/NO20082122L/no not_active Application Discontinuation
-
2010
- 2010-08-04 US US12/850,330 patent/US8153623B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20100324022A1 (en) | 2010-12-23 |
| US8153623B2 (en) | 2012-04-10 |
| EP1934176A1 (en) | 2008-06-25 |
| NZ567030A (en) | 2011-03-31 |
| CR9926A (es) | 2008-07-29 |
| CA2625763A1 (en) | 2007-04-19 |
| ATE543797T1 (de) | 2012-02-15 |
| US7803833B2 (en) | 2010-09-28 |
| EP1934176B1 (en) | 2012-02-01 |
| KR20080059297A (ko) | 2008-06-26 |
| TW200728258A (en) | 2007-08-01 |
| NO20082122L (no) | 2008-07-02 |
| AU2006301471A1 (en) | 2007-04-19 |
| WO2007042240A1 (en) | 2007-04-19 |
| AR057869A1 (es) | 2007-12-26 |
| US20080293753A1 (en) | 2008-11-27 |
| BRPI0617189A2 (pt) | 2011-07-19 |
| ES2381686T3 (es) | 2012-05-30 |
| IL190544A (en) | 2013-06-27 |
| JP2009514801A (ja) | 2009-04-09 |
| IL190544A0 (en) | 2008-11-03 |
| EA200801068A1 (ru) | 2009-02-27 |
| PE20070495A1 (es) | 2007-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8153623B2 (en) | Compounds | |
| US20100105754A1 (en) | 5-(4phenyl)prolinamide for treatment of epilepsy | |
| EP3675848B1 (en) | Spirocycle compounds and methods of making and using same | |
| JP5139307B2 (ja) | ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体 | |
| US20100130583A1 (en) | Prolinamide derivatives as modulators of voltage-gated sodium channels | |
| US20160185758A1 (en) | 2-(Pyridin-2-yl)-1, 7-Diaza-Spiro [4.4] Nonane-6-One Compound as Voltage-Gated Sodium Channel Modulator | |
| JP6483105B2 (ja) | ピペラジン誘導体および医薬としてのその使用 | |
| CN107344942B (zh) | 调节电压门控钠通道的化合物 | |
| US8143306B2 (en) | Methods of treating bipolar disorders | |
| CN101326162A (zh) | 作为电压门控钠通道的调控剂的季铵化的α-氨基甲酰胺衍生物 | |
| HK1232519A1 (en) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091006 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091006 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120309 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120515 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120515 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120810 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121030 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121115 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5139306 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151122 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |